ONE-DAY TREATMENT OF SHIGELLOSIS WITH CIPROFLOXACINE by Nenova, M. & Nikolova, D.
Scripta Scientifica Medica, vol. 32 (2000), pp 59-62 Copyright © Medical University, Varna 
O N E - D A Y T R E A T M E N T O F S H I G E L L O S I S 
W I T H C I P R O F L O X A C I N E 
M. Nenova, D. Nikolova 
Department of Infectious Diseases, Medical University of Varna 
A B S T R A C T 
The considerable epidemic potential of Shigelloses in extreme situations determines their socio-medical signif­
icance and therapeutic challenge. In the First Infectious Clinic, Department of Infectious Diseases and Epide­
miology, Medical University of Varna, 30 patients aged between 18 and 51 years were administered 
ciprofloxacine at a dose of 500 mg twice daily for one day only. Their mean hospital stay was 7,48 ± 1,27 days 
long. The control group consisted of 24 age-matched patients treated with other chemotherapeutic drugs for 
3-5 days which mean hospitalization was 8,04 ± 2,99 days long. In 27 ciprofloxacine-treated patients the clini­
cal healing occurred on the third hospital day. The febrility disappeared and the stools normalized. The 
pathological admixtures of mucus and blood disappeared until the third day. The authors conclude that the 
one-day treatment of shigellosis with ciprofloxacine is safe and effective. The short duration of the therapy re­
duces the isolation period. No side effects are observed at all. 
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I N T R O D U C T I O N 
During the recent 3 years, the incidence rate of Shigella in­
fections in Bulgaria varies between 30 and 40 %000 mani­
fested by alternating decrease and increase (2). Obviously, 
these values are typical of this country taking into consider­
ation the present sanitary-hygienic environment and health 
education of the population. The mortality and lethality 
rates remain relatively unchanged in 1997 and 1998, too, i. 
е., of 0,11 %000 and 0,34%000, respectively (1,2). The epi­
demic process is characterized by sporadic cases and/or ep­
idemic outbreaks that prevail in children's homes, mater­
nity homes, social care homes, psychiatric clinics, etc. 
The morbidity rate of Shigellosis increases in some coun­
tries like Chile but decreases in other ones like Poland 
(11,14). The considerable epidemic potential of Shigelloses 
in extreme situations determines their socio-medical signif­
icance and therapeutic challenge. The management strategy 
is complicated by the continuously enlarging multi-drug re­
sistance of a series of Shigella strains towards gentamycin, 
chloramphenicol, TMP-SMX, ampicillin, cephalosporins, 
etc. (4-9,11,14). On the contrary, a preserved susceptibility 
towards quinolones has recently been reported (7-9,11). 
The epidemic course of bacterial dysentery in the town and 
region of Varna, Bulgaria, in summer necessitates a timely 
looking for new therapeutic schedules for this disease. 
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Since 1973, an important task of the Department of Infec­
tious Diseases, Medical University of Varna, consists in the 
creation of a shortened therapeutic course of Shigella infec­
tions. A lot of combinations of chemotherapeutic drags ap­
plied at an optimal dosage for 24 or 48 hours have already 
been approved (10) (Table 1). 
Table I . Therapeutic combinations for Shigellosis 

























6. TMP-SMZ 3 x 0,48 
7. 
Ampicillin 
Streptomycin per os 
4x0,5 
4x 1,0 
As there are reports in the literature available about the us­
age of ciprofloxacine in the management of Shigella infec-
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tions (3) we decided to prove the effectiveness of a short­
ened schedule in our patients, too. 
The aim of the present study is to follow-up the opportuni­
ties for one-day treatment of Shigellosis with 
ciprofloxacine based on literature data available 
(2,3,12,13). 
M A T E R I A L AND M E T H O D S 
Out of a total of 196 bacterial dysentery cases in the town 
and region of Varna, Bulgaria, 57 patients aged over 14 
years and hospitalized in the First Infectious Clinic, Depart­
ment of Infectious Diseases and Epidemiology, in 1998 
were followed-up. Thirty patients aged between 18 and 51 
years (at a mean age of 20,79 ± years) were administered 
ciprofloxacine at a dose of 500 mg twice daily for one day 
only. With 24 soldiers in a military outfit (80 % of the 
cases), S. sonnei was isolated, in 3 patients (10 % of the 
cases), S.flexneri 2a was found; in two patients (6,67 % of 
the cases) S.flexneri la was established, but in one patient 
(3,33 % of the cases) both S. sonnei and S.flexneri lb were 
proved (Fig. 1). The distribution of the Shigella strains in 
the control group is demonstrated on Fig. 2. 
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R E S U L T S AND D I S C U S S I O N 
Some of our data are illustrated on Tables 2 and 3. 
Table 2 shows the characteristics of Shigellosis in the pa­
tients with ciprofloxacine therapy and in the control pa­
tients. 
The sensitivity of the different Shigella strains towards 
some chemotherapeutic means is demonstrated on Table 3. 
It should be mentioned that the epidemic outbreak in the 
military outfit was due to the poor sanitary-hygienic condi­
tions and causing a contact mechanism of infection. Pa­
tients' hospitalization was performed on the second and 
third day after the onset of complaints. One soldier was an 
infection carrier and did not demonstrate any clinical symp­
toms of the disease. 
The clinical course was typical of the disease manifested by 
a moderately severe colitis and febrile intoxication syn­
drome with the rest patients. There was a certain 
dehydratation was noted in 17 patients necessitating a 
supplementation of a peroral and parenteral rehydratation 
along with the etiologic therapy. The isolation of S. Sonnei 
coincided with the increasing incidence rate of this strain in 
other epidemic outbreaks in the country. In 1998, S.flexneri 
was isolated in 63 % but S. sonnei in the rest 37 % of the 
cases (2). Ciprofloxacin therapy started after taking the 
samples for microbiological testing already at the day of 
hospitalization. 
One-day treatment of shigellosis with ciprofloxacine 
Table 2. Characteristics of Shigellosis 
No Parameters Ciprofloxacine group (n=30) 
Control group 
(n=24) 
1. Prehospital duration of disease (days) 1чЗ (1,75±1,47) 1чЗ (2,10±1,20) 
2. 
Stool frequency before treatment / 
24 h (3-4 4 15-20) 
29 (96,67 % ) 24(100%) 
3. Vomiting 0 4(16,67%) 
4. Anorexia 29 (96,67 % ) 24(100%) 
5. Abdominal pain 27(90%) 24(100%) 
6. Fever (37,3 ОС ч 40 ОС) 17(56,67%) 16(80%) 
7. Abdominal tenderness 13(43,33%) 13(54,17%) 
8. Colitis sigmoidea spastica 15(50%) 13(54,17%) 
9. Dehydratation 20(66,67%) 16(66,67%) 
10. Bloody mucoid diarrhea 25 (83,33 % ) 20 (83,33 % ) 
11. Asymptomatic patients 1 (3,33 % ) 0 
12. 
Leukocytosis: > 10 G/l 4(13,33%) 10(41,67%) 
<4G/\ 3(10%) 1 (4,17%) 
Table 3. Sensitivity and resistance of two Shigella strains to antibacterial agents 
S. sonnei S. flexneri 2a 
R(%) S(%) I ( % ) R ( % ) S(%) 
Ampicillin 100 83 17 
Piperacillin 73.33 23,33 3,34 88 12 
Chloramphenicol 26,67 40 33,33 83 17 
Cephalosporins 23,33 53,33 23,34 33 45 22 
Gentamycin 50 33,33 16,67 4 % 
Amikalin 40 50 10 12 88 
TMP-SMZ 36,66 50 13,34 40 50 10 
Nalidixic acid 100 100 
Ciprofloxacine 100 100 
In 27 patients (90 % of the cases), the clinical healing oc­
curred on the third hospital day. The febrility disappeared 
and the stools normalized. The pathological admixtures of 
mucus and blood disappeared until the third day. One case 
required prolongation of the therapy with another drug, i.e., 
with nelidix. The bacteriological sanation occurred during a 
period of 5,48 ± 1,57 days in 96,67 per cent of the cases but 
-after 7,80 ± 2,53 days (t = 4,40; p < 0,001) in the control 
group. 
No side effects after ciprofloxacine application were ob­
served at all. 
C O N C L U S I O N S 
1. One-day treatment with ciprofloxacine is safe and 
exerts a very good clinical and bacteriological effect. 
2. Short duration of the therapy reduces the isolation 
period and seems, therefore, economically more 
effective. 
3. There are neither side reactions, nor unwanted effects 
after the administration of ciprofloxacine at all. 
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